Metastatic Castrate Resistant Prostate Cancer (mCRPC) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting metastatic castrate resistant prostate cancer (mcrpc) clinical trials across 24 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Amersfoort, Utrecht, Netherlands, Anaheim, California, United States, Ankara, Turkey (Türkiye). Updated daily from ClinicalTrials.gov.


Metastatic Castrate Resistant Prostate Cancer (mCRPC) Trials at a Glance

7 actively recruiting trials for metastatic castrate resistant prostate cancer (mcrpc) are listed on ClinicalTrialsFinder across 6 cities in 24 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Amersfoort, Anaheim, and Ankara. Lead sponsors running metastatic castrate resistant prostate cancer (mcrpc) studies include Hannah Schaefer, Institute of Cancer Research, United Kingdom, and ARTBIO Inc..

Browse metastatic castrate resistant prostate cancer (mcrpc) trials by phase

Treatments under study

About Metastatic Castrate Resistant Prostate Cancer (mCRPC) Clinical Trials

Looking for clinical trials for Metastatic Castrate Resistant Prostate Cancer (mCRPC)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Metastatic Castrate Resistant Prostate Cancer (mCRPC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer600 enrolled233 locationsNCT06551324
Recruiting
Phase 1Phase 2

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Institute of Cancer Research, United Kingdom78 enrolled4 locationsNCT07002320
Recruiting
Phase 1

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Prostate Cancer (CRPC)
ARTBIO Inc.80 enrolled3 locationsNCT07214961
Recruiting
Phase 1

TmPSMA-02 in mCRPC

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
University of Pennsylvania30 enrolled1 locationNCT06046040
Recruiting
Phase 2

Dose Optimisation and Prostate-Specific Membrane Antigen (PSMA) Receptor intensification with 177Lu-PSMA Therapy: A Randomised Phase II trial: OPTIMAL-PSMA

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
St Vincent's Health Network120 enrolled1 locationACTRN12625000971437
Recruiting
Phase 1

Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2)

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Jean-Mathieu Beauregard60 enrolled1 locationNCT06943495
Recruiting

Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

Metastatic Castrate Resistant Prostate Cancer (mCRPC)Kidney DiseaseRadiation Nephropathy
Hannah Schaefer100 enrolled1 locationNCT06720532